Correction to: GP2015: An Etanercept Biosimilar

被引:0
|
作者
Emma D. Deeks
机构
[1] Springer,
关键词
D O I
10.1007/s40259-018-0296-z
中图分类号
学科分类号
摘要
The article GP2015: An Etanercept Biosimilar, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 31, issue 6, pages 555–558 HEXAL AG requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by HEXAL AG. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
引用
收藏
页码:525 / 525
相关论文
共 50 条
  • [1] GP2015: An Etanercept Biosimilar
    Emma D. Deeks
    [J]. BioDrugs, 2017, 31 : 555 - 558
  • [2] GP2015: An Etanercept Biosimilar
    Deeks, Emma D.
    [J]. BIODRUGS, 2017, 31 (06) : 555 - 558
  • [3] GP2015: An Etanercept Biosimilar (vol 31, pg 555, 2018)
    Deeks, Emma D.
    [J]. BIODRUGS, 2018, 32 (05) : 525 - 525
  • [4] A TOTALITY-OF-THE-EVIDENCE APPROACH TO THE DEVELOPMENT OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR
    McCamish, M.
    DaSilva, A.
    Mayer, R. Ernst
    Fritsch, C.
    Schiestl, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1010 - 1010
  • [5] Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®)
    Hofmann, Hans-Peter
    Kronthaler, Ulrich
    Fritsch, Cornelius
    Grau, Roger
    Mueller, Stefan O.
    Mayer, Robert
    Seidl, Andreas
    Da Silva, Antonio
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (10) : 1185 - 1195
  • [6] The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar
    Strand, Vibeke
    Girolomoni, Giampiero
    Schiestl, Martin
    Mayer, Robert Ernst
    Friccius-Quecke, Hilke
    McCamish, Mark
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (06) : 993 - 1003
  • [7] NON MEDICAL SWITCH FROM ETANERCEPT ORIGINATOR TO BIOSIMILAR GP2015 IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES
    Colaci, M.
    Aprile, M. L.
    La Rosa, A.
    Di Maggio, A.
    Malatino, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1135 - 1135
  • [8] Effectiveness and safety of biosimilar etanercept GP2015 in patients with rheumatoid arthritis in the UK: results from the COMPACT study
    Askari, Ayman
    Both, Charlotte
    Martin, Angela
    Walsh, David A.
    Sheeran, Tom
    [J]. RHEUMATOLOGY, 2024, 63
  • [9] State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015
    Poetzl, J.
    Arlt, I.
    von Richter, O.
    Woehling, H.
    Afonso, M.
    Schaffar, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (04) : E130 - E132
  • [10] PHARMACOKINETICS AND SAFETY OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR, ADMINISTERED SUBCUTANEOUSLY BY AN AUTOINJECTOR OR PREFILLED SYRINGE IN HEALTHY MALE SUBJECTS
    Afonso, M.
    Kollins, D.
    Macke, L.
    Woehling, H.
    Wuerth, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 233 - 234